Mark Rowand, MD
Sports Medicine · Dallastown, PANPI 1104948702
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 433 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 49 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations.
Across 433 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$923
- Pfizer$796
- Novo Nordisk$669
- Johnson & Johnson$344
- Lilly USA, LLC$328
- plus $3K from 43 others
What the payments were for
- Speaking & faculty fees$150%
- Food & beverage$6,85899%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,926 in reported general payments places this provider in the 80th percentile of 311 sports medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 300 | $277,553 |
| OzempicSemaglutide | 81 | $159,412 |
| JardianceEmpagliflozin | 137 | $156,617 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 93 | $107,095 |
| FarxigaDapagliflozin Propanediol | 53 | $74,769 |
| MounjaroTirzepatide | 41 | $65,017 |
| XareltoRivaroxaban | 39 | $37,176 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $35,931 |
| TrulicityDulaglutide | 21 | $31,398 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $28,839 |
| OxycontinOxycodone Hcl | 12 | $21,055 |
| InvokanaCanagliflozin | 12 | $20,119 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 61 | $19,362 |
| Tresiba Flextouch U-200Insulin Degludec | 14 | $18,462 |
| MyrbetriqMirabegron | 20 | $14,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $796 | $277,553300 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Breo Ellipta, Shingrix | $923 | $186,631277 claims |
| Novo NordiskOzempic, Rybelsus | $669 | $170,22893 claims |
| Boehringer IngelheimJardiance | $171 | $156,617137 claims |
| Lilly USA, LLCMounjaro, Trulicity | $328 | $96,41562 claims |
| AstraZenecaFarxiga | $268 | $74,76953 claims |
| Johnson & JohnsonXarelto, Invokana | $344 | $57,29451 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $14,72620 claims |
| AbbVieLinzess, Synthroid | $1,096 | $11,49265 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 311 sports medicine providers in Pennsylvania.
Other sports medicine in Dallastown
- Sam AkhavanPittsburgh$2.2M
- Albert LinPittsburgh$460K
- Sommer HammoudPhiladelphia$238K
- Theresa PazionisPhiladelphia$235K
- Matthew Varacallodu Bois$129K
- Matthew BestAllentown$77K
- Marco AlcalaCanonsburg$54K
- Brandon TaubergWashington$54K
- Alexander JohnsonBethlehem$51K
- Tyler HauerPittsburgh$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.